The Effect of Treatment with an LH-RH Agonist (Buserelin) on Gonadal Activity, Growth, and Bone Maturation in Children with Central Precocious Puberty

    May 1987 in “ European Journal of Pediatrics ”
    Stenvert L. S. Drop, Roelof J. Odink, C. Rouwé, B.J. Otten, M. W. Van Maarschalkerweerd, M. H. Gons, Alice G.M. Bot, M. Meradji
    Studysummary This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment. Our plain-language summary of this paper — not a Tressless recommendation.
    The study from 1987 involved 25 children with central precocious puberty treated with the LH-RH agonist Buserelin for 11-18 months. The treatment effectively suppressed gonadal activity, as evidenced by decreased estrogen and testosterone levels, cessation of menstruation in girls, and reduced testicular volume in boys. Growth rates initially varied, with a decline observed over the subsequent year. The study concluded that Buserelin was a safe and effective method for inhibiting gonadal activity, with potential for improved final height prediction with prolonged treatment.
    Discuss this study in the Community →